Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CURVE-UC: A Pragmatic Randomized, Double-blind, Placebo Controlled, Treat-through, Multi-site Pragmatic Interventional Study to Evaluate the Efficacy and Safety of Combination Curcumin-QingDai (CurQD) With Vedolizumab in Moderate to Severe Ulcerative Colitis (UC)

NCT07665294 is registered in ClinicalTrials.gov with Ryan C Ungaro as lead sponsor.

NCT NCT07665294
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07665294 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CURVE-UC: A Pragmatic Randomized, Double-blind, Placebo Controlled, Treat-through, Multi-site Pragmatic Interventional Study to Evaluate the Efficacy and Safety of Combination Curcumin-QingDai (CurQD) With Vedolizumab in Moderate to Severe Ulcerative Colitis (UC)
Lead sponsor
Ryan C Ungaro
Phase
Phase 4
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
June 23, 2027
Enrollment
160 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis